Trigyn Technologies Announces Q2 & Half Year Results Ended September 30, 2025
Trigyn Technologies announced Q2 and half-year results ending September 30, 2025. Consolidated revenue increased, but earnings after tax decreased compared to the previous year. Standalone results also showed revenue increase but losses persisted.
The financial results indicate moderate changes in revenue and earnings, suggesting a medium impact on the company's performance.
The announcement presents a mix of positive (increased revenue) and negative (decreased earnings/losses) financial results, leading to a neutral sentiment.
* Trigyn Technologies Limited announced its financial results for the quarter and half-year ended September 30, 2025. * Consolidated revenue for the half-year ended September 30, 2025, was ₹46,645.12 Lakhs, compared to ₹45,062.04 Lakhs for the same period in 2024. * Earnings After Tax (EAT) for the half-year ended September 30, 2025, was ₹66.32 Lakhs, compared to ₹797.68 Lakhs in the previous year. * Consolidated revenue for the quarter ended September 30, 2025, was ₹24,195.14 Lakhs, compared to ₹22,449.99 Lakhs in the previous quarter ended June 30, 2025. * EAT for the quarter ended September 30, 2025, was ₹527.21 Lakhs, compared to a loss of ₹(460.87) Lakhs in the previous quarter. * Standalone revenue for the half-year ended September 30, 2025, was ₹7,883.22 Lakhs, compared to ₹7,090.82 Lakhs in the same period in 2024. * Standalone loss for the half-year ended September 30, 2025, was ₹(651.02) Lakhs, compared to a loss of ₹(757.66) Lakhs in the previous year. * Standalone revenue for the quarter ended September 30, 2025, was ₹4,342.20 Lakhs, compared to ₹3,541.02 Lakhs in the previous quarter ended June 30, 2025. * Standalone loss for the quarter ended September 30, 2025, was ₹(152) Lakhs, compared to a loss of ₹(499.02) Lakhs in the previous quarter.
What to do with a filing like this
Trigyn Technologies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Trigyn Technologies Limited. Read the original for the full detail.